Key information
- The R21/Matrix-M vaccine was launched in Nigeria as part of a historic initiative to immunize children aged five to eleven months.
- The program aims to combat malaria, one of the deadliest diseases in the world, and will be administered to over 800,000 children in Kebbi and Bayelsa states.
- The vaccine has been shown to be effective, providing up to 77 percent protection against malaria, and its introduction is expected to strengthen existing preventive measures such as insecticide-treated bed nets and insecticides.
Nigeria has taken a major step in its fight against malaria by launching a historic childhood vaccination initiative. Starting December 2, 2024, the R21/Matrix-M vaccine will be administered to children aged five to eleven months in Kebbi and Bayelsa states, areas heavily affected by the disease. This program is a key part of the government’s overall strategy to combat malaria, one of the world’s deadliest diseases.
At the launching ceremony in Birnin Kebbi, Dr Kamal Musa of the National Primary Health Care Development Agency (NPHCDA) highlighted the importance of this vaccination program for parents and urged them to bring their children aged five to eleven months to the nearest hospital to be vaccinated. This initiative goes beyond immediate health benefits; it reflects Nigeria’s commitment to improving the well-being of its youngest citizens.
A persistent problem
Malaria remains a persistent problem in Nigeria, where it accounts for more than 27 percent of the global disease burden. Each year, the disease claims around 200,000 lives among children under the age of five. Dr Nasiru Zurmi, World Health Organization (WHO) representative at the event, highlighted the devastating impact of malaria on the nation.
The introduction of the R21/Matrix-M vaccine is expected to strengthen existing prevention measures, such as treated mosquito nets and insecticides. According to the WHO, the vaccine has been shown to be effective, providing up to 77 percent protection against malaria. This is therefore a glimmer of hope in reducing the devastating effects of malaria on Nigerian children.
Global collaboration and engagement
The rollout includes more than 800,000 doses delivered through the collaboration of organizations such as Gavi, WHO and UNICEF, demonstrating global commitment to the fight against malaria. Dr. Muyi Aina, Executive Director of the NPHCDA, emphasized that the vaccine will be integrated into routine immunization programs, demonstrating a long-term commitment to its impact.
The aim is to extend the vaccination program to the entire country. The NPHCDA aims to include the malaria vaccine in the national immunization schedule, thereby ensuring access to millions of Nigerian children. This ambitious plan will extend beyond Kebbi and Bayelsa, encompassing 19 other states by the following year. Developed by the University of Oxford, the R21/Matrix-M vaccine is based on innovative technology initially intended for various viral infections.
Economic benefits and community engagement
Its deployment not only represents hope for improved health, but also potential economic benefits for Nigeria. Malaria currently causes annual economic losses exceeding $1.1 billion, mainly due to health care costs and reduced productivity. Effective vaccination coverage could ease this burden.
The 11-month-old son of local resident Happiness Idia-Wilson was one of the first to receive the vaccine. She expressed excitement about the importance of this vaccine for her child’s safety. She plans to encourage other mothers to vaccinate their children, highlighting the critical role community engagement plays in immunization success.
Government commitment and future plans
The Nigerian government has recently made significant progress with the establishment of the AMEN (Advisory on Malaria Elimination in Nigeria) project. At his inaugural meeting, Minister of Health, Professor Ali Pate, recognized that malaria was not only a health crisis, but also an economic and development challenge, underscoring the government’s renewed commitment to tackle this problem head on.
Beyond health statistics, malaria exacerbates poverty and hinders development. For Nigerians, especially children and pregnant women, effective preventive measures such as the lauded malaria vaccine are key to changing the situation. WHO’s Dr. Walter Mulombo expressed optimism that, along with other prevention methods, this vaccine will significantly reduce the burden of malaria and bring WHO closer to its goal of eradicating the disease.
Conclusion
By launching the R21 vaccination campaign, Nigeria is paving the way for a healthier future. Cooperation between the government, health agencies and international partners highlights the urgency of combating the effects of malaria on the country’s children.
If you want access to all articles, subscribe here!
